Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions
- 1 November 1999
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 84 (9) , 11-19
- https://doi.org/10.1016/s0002-9149(99)00697-9
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- From First Class to Third Class: Recent Upheaval in Antiarrhythmic Therapy-Lessons from Clinical TrialsThe American Journal of Cardiology, 1996
- The Coming of Age of the Class III Antiarrhythmic Principle: Retrospective and Future TrendsThe American Journal of Cardiology, 1996
- Newer developments in the management of atrial fibrillationAmerican Heart Journal, 1995
- Amiodarone: Pharmacology, Clinical Actions, and Relationships Between ThemJournal of Cardiovascular Electrophysiology, 1992
- Antiarrhythmic Drug ClassificationsDrugs, 1991
- What is an antiarrhythmic drug? From clinical trials to fundamental conceptsThe American Journal of Cardiology, 1990
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Risk factors for the development of proarrhythmic eventsThe American Journal of Cardiology, 1987
- Intramuscular Lidocaine for Prevention of Lethal Arrhythmias in the Prehospitalization Phase of Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogsThe American Journal of Cardiology, 1977